Clinical Trial Search

Primary: Number of Sexual Partners, 3 Months Post Intervention — 2.19; 2.04; 2.14; 2.13 number of partners

Primary: Change in Prevention Self-efficacy — 1.87; 0.20 score on a scale — p=0.04

Primary: Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms — 0.07; 1.03 event rate per 100 person-yr — p=<0.0001

Primary: Number of Participants That Schedule a Pre-test Session — 74 Participants

Primary: GC/CT Detection Rates — 15.2; 12.1; 11 No. of patients with positive GC/CT

Primary: Concordance Between Vaginal Self-swab Results and Provider-collected Cervical Swab Results for HPV DNA Among Sexually Active FTM Adults — 15; 2; 6; 108 Participants…

Primary: Epithelial Disruption Graded by a Pathologist Blinded to Study Intervention. — 1.0; 1.17 units on a scale — p=<0.05

Primary: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups — 684; 696 Participants

Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale

Primary: Qualitative Summaries of Participant Experience in Focus Group Discussions — 100; 7; 26; 10 number of times reported in FGD

Primary: Feasibility of Integrating Point-of-care Testing (Monitoring & Evaluation Indicators) — 396; 378; 399; 216 Participants

Primary: Syphilis Tests Undertaken — 29; 37 Participants

Primary: HPV Incidence Rates, Expressed as Incident Infections/1000 Infection-months at Risk. These Were Calculated Separately for Females and Males Across the Four Vaccine…

Primary: Doxycycline Concentration in Rectal Tissue — 2.330 µg/g

Primary: Feasibility as Assessed by the Number of Participants Who Are Enrolled With a Partner — 17; 17 Participants

Primary: Incidence Rate of Ng Plus Ct Detected at Any Site Whilst Individuals Are Screened vs. Not Screened — 0.155; 0.205 Ng or CT cases per study visit

Primary: Dual Protection Behaviors, Reported in Surveys and Reviewed in the Medical Record. — 7; 6; 8; 8 Participants

Primary: HIV Self-testing With Online Supervision Past 6 Months at Baseline — 50; 44 Participants

Primary: HIV Transmission Risk Behavior — 9; 11; 0; 4 Participants — p=0.20

Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened

Primary: Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment With Metronidazole (MTZ) — 58; 34 Participants

Primary: The Competitive Index of the Mutant Compared to Wild Type Proportion of Organisms With the Predicted Competitive Advantage Recovered From Urine and/or Urethral Swab…

Primary: Number of Subjects Who Had New Sexual Relationships — 56; 37; 61 Participants

Primary: Number of Male Clients Who Will Undergo Circumcision (Uptake of VMMC) — 8; 25; 13; 17 Participants — p=0.044

Primary: Consistent (100%) Condom Use — 9; 6; 7; 7 Participants — p=<.05

Primary: Self-reported Consistent Condom Use During Vaginal Intercourse in the Past 3 Months — 121; 103; 125; 93 Participants — p=.008

Primary: Mean Condom Use — 0.50; 0.14; 1.30; 0.52 sexual episodes

Primary: Self-reported HIV or STI Testing in Past 3 Months — 76; 88 Participants — p=0.914

Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale

Primary: Viral Copy Number in 30-minute Exhaled Breath Sample — 38,000; 12,000 Fine aerosol RNA copy number